Delta-Fly Pharma, Inc. Stock

Equities

4598

JP3549370009

Pharmaceuticals

Delayed Japan Exchange 09:50:22 2024-06-17 pm EDT 5-day change 1st Jan Change
558 JPY -0.89% Intraday chart for Delta-Fly Pharma, Inc. +1.27% -45.02%
Sales 2022 300M 1.9M Sales 2023 - Capitalization 6.56B 41.63M
Net income 2022 -967M -6.14M Net income 2023 -1.33B -8.43M EV / Sales 2022 18.9 x
Net cash position 2022 1.27B 8.05M Net cash position 2023 844M 5.36M EV / Sales 2023 -
P/E ratio 2022
-7.17 x
P/E ratio 2023
-4.39 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 78.76%
More Fundamentals * Assessed data
Dynamic Chart
Delta-Fly Pharma Inc. Receives Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 Combined with Venetoclax CI
Delta-Fly Pharma Inc. Announces FDA Submission of the Protocol of the Phase I/II Study of DFP-10917 Combined with Venetoclax in the AML Patients Treated by VTX in the AML CI
Delta-Fly Pharma Inc. Announces Abstracts Submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO Annual Meeting CI
Delta-Fly Pharma Inc Announces Initiation of Phase III Pivotal Comparative Clinical Trial of DFP-14323 CI
Delta-Fly Pharma, Inc. Provides Update on Interim Analysis Status of Phase III Study of DFP-10917 in Patients with R/R AML CI
Delta-Fly Pharma, Inc. announced that it has received ¥503.7238 million in funding from Nippon Chemiphar Co., Ltd. CI
Delta-Fly Pharma, Inc. announced that it has received ¥1.300842 billion in funding from Macquarie Group Limited CI
Delta-Fly Pharma, Inc. announced that it expects to receive Ñ1.300842 billion in funding from Macquarie Group Limited CI
Delta-Fly Pharma, Inc. announced that it has received ¥5.67 million in funding from Mizuho Securities Co., Ltd., Investment Arm CI
Delta-Fly Pharma, Inc. announced that it expects to receive ¥5.67 million in funding from Mizuho Securities Co., Ltd., Investment Arm CI
Delta-Fly Pharma Enters into Licensing Agreement with Nippon Chemifa CI
Delta-Fly Pharma, Inc. Initiates Phase 3 Clinical Study of DFP-10917 and Phase 1 Clinical Study of DFP-14927 CI
Certain Common Shares of Delta-Fly Pharma, Inc. are subject to a Lock-Up Agreement Ending on 9-JAN-2019. CI
Delta-Fly Pharma, Inc. has completed an IPO in the amount of ¥3.339 billion. CI
Delta-Fly Pharma, Inc. has filed an IPO. CI
More news
1 day-0.89%
1 week+1.27%
Current month+6.08%
1 month-7.00%
3 months-35.86%
6 months-31.11%
Current year-45.02%
More quotes
1 week
536.00
Extreme 536
580.00
1 month
451.00
Extreme 451
639.00
Current year
451.00
Extreme 451
1 078.00
1 year
451.00
Extreme 451
1 825.00
3 years
451.00
Extreme 451
2 085.00
5 years
451.00
Extreme 451
2 740.00
10 years
451.00
Extreme 451
5 380.00
More quotes
Managers TitleAgeSince
Founder 74 10-12-05
Chief Administrative Officer 59 19-08-31
Chief Tech/Sci/R&D Officer 61 12-03-31
Members of the board TitleAgeSince
Founder 74 10-12-05
Chief Tech/Sci/R&D Officer 61 12-03-31
Director/Board Member 63 16-07-31
More insiders
Date Price Change Volume
24-06-17 558 -0.89% 49 600
24-06-17 563 +0.72% 118,700
24-06-14 559 -1.24% 140,500
24-06-13 566 +1.98% 79,500
24-06-12 555 +0.73% 55,000

Delayed Quote Japan Exchange, June 17, 2024 at 09:50 pm EDT

More quotes
Delta-Fly Pharma, Inc. is a Japan-based company principally engaged in the research, development, manufacture and sale of pharmaceuticals. The Company's development pipeline includes anticancer drug candidate compound DFP-10917 whose target disease is refractory or recurrent acute myelogenous leukemia, anticancer drug candidate compound DFP-14323 whose target disease is lung cancer, anti-cancer drug candidate compound DFP-11207 whose target disease is solid cancer, anticancer drug candidate compound DFP-14927 whose target disease is solid cancer or blood cancer, anticancer drug candidate compound DFP-10825 whose target disease is peritoneal dissemination metastatic cancer.
More about the company